The global COPD and asthma devices market would reach $34.3 billionby 2020, Finds New Report

"Global COPD and Asthma Devices Market - Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013 - 2020", the global COPD and asthma devices market would reach $34.3 billionby 2020, registering a CAGR of 4.5% during 2014 - 2020. Considering the growth and market size, Dry Powder Inhalers (DPIs) will be the most lucrative market segment of the COPD and Asthma devices (inhalers) market by 2020.

Metered Dose Inhalers (MDIs) are the largest revenue generating segment currently and would maintain the stand till 2020.The need for urgency in medication and portability of the drug delivery devices will drive the growth for COPD and Asthma devices. Despite notable advantages of the COPD and Asthma devices, some factors such as environmental concerns are likely to impede the growth of COPD and Asthma devices market. It is observed that the inhalers, particularly the MDIs, release environmentally-hazardous gases, namely chlorofluorocarbon (CFC) and hydrofluoroalkanes (HFA), which is negatively impacting growth of the MDIs segment.

Consumption pattern will shift to better alternatives, namely the DPIs. The Soft Mist Inhalers (SMIs), which are another type of inhalers, deliver metered dosage of medication as a soft mist. Such form of drug delivery is ~65% to 80% more efficacious than its peers and will eventually display higher growth as compared to its peers.

Nebulizers, electric or battery powered machines that dispense medication as a fine mist, are ideal for home healthcare set-up for debilitated patients, geriatrics and children. Nebulizers segment thus holds about 13% of the global COPD and Asthma devices market; however, the nebulizers market is forecast to have diminishing growth through 2020 as nebulizers are rendered ineffectual, as POC or portable COPD and Asthma devices due to its larger set up.

Key findings of the study:

• Drug powder inhalers (DPIs) segment will grow at a CAGR of 5.3% during the forecast period, fastest among all
• North American market would be one of the most lucrative markets, in terms of growth
• European market for COPD and asthma devices would reach $10 billion by 2020, with the CAGR of 4.8%
• Within the nebulizers segment markets, compressor nebulizers would be most lucrative, growing at 7% CAGR during the forecast period and compressor nebulizers would garner 81.5% market share by 2020
• Specific focus to achieve product differentiation and thus gain competitive advantage drives the development of new product variants of COPD and Asthma devices. In accordance to the afore-mentioned trend, the market has witnessed steady stream of product launch. Key product manufacturing companies profiled in the report include GlaxoSmithKline Plc, Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Philips Healthcare, 3M Health Care, Allied Healthcare Products Inc., Sunovion Pharmaceuticals Inc., GF Healthcare Products, Smith Medicals, Lincare Holdings Inc. and Baxter International.

Spanning over 130 pages, 57 Tables and 23 Figures “Global COPD and Asthma Devices Market (Product Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020” report Covering Introduction, Executive Summary, Market Overview, Global Copd And Asthma Devices Market By Product Type, 2013-2020, $Million, Global Copd And Asthma Devices Market By Geography, 2013-2020, $Million, Company Profiles. This report Covered These Companies - GlaxoSmithKline Plc, Novartis AG, Merck & Co., Inc., Philips Healthcare, AstraZeneca Plc, 3M Health Care, Allied Healthcare Products Inc., GF Health Products Inc., Sunovion Pharmaceuticals Inc., Smith Medicals, Lincare Holdings Inc., Baxter International.

Know more about this report at – http://mrr.cm/4kS

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices

The global catheters market would reach $42.5 billion by 2020, Finds New Report

"Global Catheters Market - Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013 - 2020", the global catheters market would reach $42.5 billion by 2020, registering a CAGR of 7.5% during 2014 - 2020. Increased usage of catheters in minimally invasive surgeries and the introduction of technologically advanced catheters with improved efficacy contribute to growth of the global catheters market.

Cardiovascular catheters are the largest revenue generating segment in the overall catheters market.Growing prevalence of cardiovascular diseases, diabetes and urinary diseases is expected to boost demand for catheters. According to data, 2012 approximately 74,690 new cases of urinary bladder cancer were diagnosed (incidence rate) and it is estimated that, approximately 0.5 million people suffer from urinary bladder cancer (prevalence rate) annually in the United States.

Also, catheters are vital component/medical consumable used during several diagnostic procedures. Overall, similar consumption pattern for catheters witnessed in several other medical conditions - has resulted in increased usage of catheters thereby increasing the market size of the global catheters market.

Promoting the further use/adoption of catheters is innovation and development of variants that overcome drawbacks of the conventional catheters; for instance, development of male external catheters minimize chances/incidences of urinary tract infection resulting from insertion of catheters in the patient's body.

High cost involved in cardiac and neurological procedures and lack of experienced and skilled professionals limit the growth of the global catheters market. Also, increasing incidences of nosocomial infections; for example, catheter-associated urinary tract infections are among the prime factors restricting growth of urological catheters market.

Going forward, developing regional - India and China catheters markets are expected to offer potential opportunities owing to increasing awareness and adoption of minimally invasive procedures (that necessitate usage of catheters). 

Key findings of the study:

• Cardiovascular catheters segment expected to grow at a CAGR of 7.4% during the forecast period, fastest among all
• Urological catheters is the fastest growing segment growing at the CAGR of 8.2% market share by 2020
• Currently, North America garners a majority share in the catheters market, in terms of market size. North America would reach$16 billion by 2020, with highest CAGR of 5.5%
• Asia Pacific market is expected to grow at 8.8% CAGR during the forecast period from 2014-2020 due to improved healthcare infrastructure in emerging economies such as India and China (promoting increased usage of catheters)
• Reimbursement for catheters or catheterization procedure varies per product. Recently, enabling regulation i.e. the department of Veterans Affairs (VA), recommended a change in the reimbursement of urological catheters - increasing coverage up to 200 sterile single use catheters per month. Such change in policies is therefore estimated to result in an increased market share of urological catheters.

Key companies profiled in the report are Boston Dickinson Ltd, Bard Medicals, Boston Scientific, Hollister Inc., Edwards Lifesciences, B. Braun Melsungen, Arrow Internationals Inc., Medtronic Inc., Medrad (Bayer AG), Johnson&Johnson and Abbott Laboratories.  Companies operating in the catheters market focus on several strategies such as product launch, collaboration and acquisition. For example, Bard Medicals's R&D spend of ~8% of the total revenue is intended for development and commercialization of feature-enhanced catheters; overall driving growth of the global catheters market.

Spanning over 110 pages, 64 Tables and 24 Figures “Global Catheters Market (Product Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020” report Covering Introduction, Executive Summary, Market Overview, Global Catheters Market By Product Type, Global Catheters  Market By Geography, Company Profiles. This report Covered 13 Companies - Abbott Laboratories, Becton Dickinson Inc., Boston Scientific, Bard Medicals, Braun Melsungen AG, Arrow International Inc., Johnson and Johnson, Medtronic Inc., Rochester Medical Co, Edwards Lifesciences, Hollister Inc., Medrad (Bayer AG), Vascular Solutions.

Know more about this report at – http://mrr.cm/4kG

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, New Report Launched

The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the world’s biopharma companies

Description

The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the world’s biopharma companies. The report provides a detailed understand and analysis of how and why companies enter manufacturing and supply deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all manufacturing and supply deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual manufacturing and supply contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of manufacturing and supply dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in manufacturing and supply deal making as well as a discussion on the merits of the type of deal.

Chapters 3 and 4 provide an overview of the structure of manufacturing and supply deals. The chapter includes numerous case studies to enable understanding of both pure manufacturing and supply deals and multicomponent deals where manufacturing and supply forms a part.

Chapters 5 and 6 provide a review of the leading manufacturing and supply deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech, most active big pharma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 7 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of manufacturing and supply deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of manufacturing and supply deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapters 9 and 10 provide a comprehensive and detailed review of manufacturing and supply deals signed and announced since 2009 for all pharma, biotech, device and diagnostics companies where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.

In addition the report includes a comprehensive listing of all manufacturing and supply deals announced since 2009.

Each listing is organized as an appendix by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in manufacturing and supply dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about manufacturing and supply alliances.

Benefits

Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:

• In-depth understanding of manufacturing and supply partnering deal trends since 2009
• Insight into the terms included in a manufacturing and supply agreement, together with real world clause examples
• Identify leading manufacturing and supply deals by value since 2009
• Identify the most active manufacturing and supply dealmakers since 2009
• Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
• Full listing of manufacturing and supply deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
• Comprehensive access to over 2,500 manufacturing and supply deals entered into by the world’s biopharma companies, together with contract documents if available
• Detailed access to actual manufacturing and supply contracts entered into by the leading fifty big pharma and big biotech companies
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Spanning over 3898 pages and 19 Figures “Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics” report Covering Executive Summary, Introduction, Trends in manufacturing and supply dealmaking, Overview of manufacturing and supply deal structure, Overview of supply deal structure, Leading manufacturing deals, Leading supply deals, Big pharma manufacturing and supply deals, Big biotech manufacturing and supply deals, Manufacturing deals contracts directory, Supply deals contracts directory. This report Covered Many Companies Few are - 1A Pharma, 3D Biomatrix, 3M, 3M Drug Delivery Systems, 3SBio, 3SI Security Systems, 454 Life Sciences, 4SC, 5LINX, A*STAR Bioprocessing Technology Institute, A5 Labs, Aalborg University Hospital, Aastrom Biosciences, Abattis Bioceuticals, Abaxis, Abbott Japan, Abbott Laboratories, Abbott Medical Optics.

Know more about this report at – http://mrr.cm/Zvr

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Partner Search – Medical Compression Stockings Market in Thailand, New Report Launched

The objective of this study was to:

• Understand market environment including competitor and distribution channel in the medical compression therapy sector.
• Recommend potential channel partners on a basis of their presence and position within the Thai market
• Provide appropriate recommendations on potential channel partners

Market size:

In 2009, feed consumption  in China, Indonesia, Philippines and Vietnam was total about 409.3 million of which China is the largest market (90% shared) followed by Indonesia and Vietnam (shared about 4% each) and Philippines (2%). 

Market attractiveness:

However, in term of market attractiveness, Vietnam  and Philippines are the most attractive markets due to reliance on imported ingredients.  In China, despite its huge market, only 1.1% of its feed consumption are imported. However, due to its substantial market size its portion of imported ingredients can be as high as 4 million tons a year.  For Indonesia, the market is self-sufficient especially for macro ingredients, while its still relies on the import market for feed supplement and additive products.

Livestock sector:

Swine and poultry feeds dominate the four markets as about 68% of livestock outputs come from these two sectors.  China is a huge market for all type of livestock's products.  Within selected Southeast Asia (SEA) markets, Indonesia is the primary market for poultry feeds, whilst the Philippines and Vietnam are the main market for swine feeds.  The dairy and beef sectors are yet to be developed in China and the selected SEA market.

Choice of feeds:

Corn, cassava, soya bean and rice bran are common macro ingredient used.  For feed supplements, nutritional products such as vitamin, amino acid and trace mineral are commonly found in the four markets, similar to auxilary substances such as pigments, antioxidant.  For disease preventing drugs, antibiotics are commonly used while growth promotants and digestive enhancers are still at an experimenting stage.

Trends of feeds ingredients:

The demand for DDGs is rising in China, Vietnam and Philippines,  This is because its considerably cheaper  than corn and the price is also more stable.   As the feeds industry in the four markets are under restructuring and moving toward industrialization, the demand for feed supplements and additive will continue to rise as its standard practice for large feed mills to use supplements and additives to improve their production capacity and maintain quality of output.  

Decision making process:

Nutritionist is the main decision maker for large feed millers.  Large feed millers are usually foreign owned and most of the time the feed formulae comes from the regional headquarter, which also plays a vital role on selection of suppliers and sourcing.  

Decision criteria:

Ability to maintain feed ingredient quality is the key issues for the selected SEA markets, while the China market is more concerned on logistical issues, such as consistent and reliable delivery and shelf life.

Key players:

CP group from Thailand, New Hope from China and San Miguel  from the Philippines are the main regional players for agribusiness.   They are vertical integrated players mainly in the poultry and swine segments.   Cargill from the U.S. and Proconco from France are also present in the selected SEA markets.   For second tier players, most are local and/or state-owned enterprises - they usually adopt a good practice from market leader.  This also includes their ingredient sourcing as well as type of feed ingredients to use.

Recommended products: 

DDGs  has high potential to grow in China, Vietnam and Philippines markets whilst Indonesian would prefer to source corn locally as the local corn price is cheaper.  The demand for functional feed supplements and additive such as nutritional enhancer, antibiotics will continue to grow  along the expansion of manufactured feed productions.  More advance technology products such as pre-biotic, pro-biotic are yet to be widely adopted and the demand will grow slowly in the short-run.   The demand for alfalfa will also continue to grow, however, price is the main barrier for adoption as most of the farmer in dairy sectors are local enterprise.  Silage inoculants still do not show a high potential for China and the selected SEA markets.  This is because most of the farmers are not aware on its functional benefits.  This therefore leads to low demand, which leads to the product not being commonly available.

Spanning over 59 pages “Market analysis - Channel: Partner Search – Medical Compression Stockings Market in Thailand” report Covering Project background, Overview of Thailand healthcare industry, Overview of medical compression stock, Market size and growth, Distribution channel analysis, Customer analysis, Appendix. This report Covered 4 Companies - Medi, Venosan, Maxis and Jobst, HAN Biomed.

Know more about this report at – http://mrr.cm/Zv8

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Peptide Therapeutics Pipeline Database: 1-Year Subscription, New Report Launched

Subscription to Publisher’s proprietary Peptide Therapeutics Pipeline Database provides online access to Peptide Therapeutics on the market and in research & development. The peptide segment database contains about 900 files.

Each project (file) is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic peptides is intuitive. Data sets of interest can be printed and exported in Word or Excel format. Projects are being updated continuously by passive and active searches. Information from press releases is entered on a daily basis. Active searches for targets, indications, company pipelines, scientific congresses, corporate releases, publications and in other sources are conducted on a rotating, regular basis.

The R&D history of each project with online references of information sources can be viewed and printed. The projects can be segmented into Territories, Therapeutic Areas and R&D Phases. A scroll down menu for predefined targets and therapeutic areas (e.g. Anti-Inflammatory Peptides) conveniently selects projects of interest:

• Anti-Infective Peptides
• Anti-Inflammatory Peptides
• Cardiovascular Peptides
• Cardiometabolic Peptides
• Cancer Peptides
• GLP-1 Receptor Agonists (only peptides)
• PTH Receptor Agonists (only peptides)
• Peptides Sales in 2013

An advanced search function allows to combine search parameters. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase, therapeutic area or company name. Sample screenshots illustrate the database.

Benefits from the Therapeutic Peptide Pipeline Database:

• Intuitive use
• 24/7 online access to database via internet
• Designed for structured searches
• Focused on targets, therapeutic areas and R&D phases
• Ideal for competitor analysis (companies, targets, therapeutic areas)
• Cost-effective and rapid solution for benchmarking
• Identification of licensing candidates
• 2013 sales figures of major peptide therapeutics

Project listing in a tabular format:

• Drug Codes
• Target / Mechanism of Action
• Class of Compound
• Product Category
• Company
• Territory
• Therapeutic Area
• Indication
• R&D Phase

Therapeutic Areas:

• Cardiovascular & blood
• Dermatology
• Gastrointestinal
• Genitourinary, renal & gynecology
• Infectious & toxicology
• Metabolism & endocrine
• Neurology & psychiatry
• Oncology
• Ophthalmology & otorhinolaryngology
• Orthopedics, dental, anesthesia & surgery
• Pulmonary & respiratory
• Rheumatoid & autoimmune

Know more about this report at – http://mrr.cm/ZCo

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

R&D Drug Pipeline Database: 1-Year Subscription, New Report Launched

R&D Drug Pipeline Database provides online access to more than 17,000 project entries in all therapeutic areas and product categories. Each project is specified for its Target or Mechanism of Action, Product Category, Therapeutic Area, indication and R&D Phase. Use of the R&D database of marketed and investigational drugs is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major products are provided. The projects can be segmented into Therapeutic Areas, Territories, Product Categories and R&D Phases. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets conveniently selects projects of interest. By clicking on column headers, projects can be arranged and listed/displayed in ascending or descending alphabetical or numerical order, e.g. for R&D phase, product category or company name.

Benefits from the R&D Drug Pipeline Database:

• Intuitive use
• Designed for structured searches
• Focused on targets, product categories and R&D phases
• Ideal for competitor analysis (companies, targets, product categories)
• Cost-effective and rapid solution for benchmarking
• Identification of licensing candidates

Project listing in a tabular format:

• Drug Codes
• Target / Mechanism of Action
• Class of Compound
• Product Category
• Company
• Territory
• Therapeutic Area
• Indication
• R&D Phase

Product Categories:

• Antibody
• Cell
• DNA
• Medical Device / Biomaterial
• Peptide
• Protein
• Radiopharmaceutical
• RNA
• Small Molecule
• Vaccine
• Therapeutic Areas
• Cardiovascular, blood & acute care
• Dermatology
• Gastrointestinal
• Genitourinary, gynecology & renal
• Infectious & toxicology
• Metabolism & endocrine
• Neurology & psychiatry
• Oncology
• Ophthalmolgoy & otorhinolaryngology
• Orthopedics, dental, anesthesia & surgery
• Pulmonary & respiratory
• Rheumatoid & autoimmune

Examples of Predefined Targets of the Scroll Down Menu:

• Anti-Infective Antibodies
• Antibody-Drug Conjugates (ADC)
• Biologic & Immune Therapy of S. aureus Infections
• c-MET/HGF Inhibitors
• CD20 Antibodies
• Coagulation Factors
• CXCR and CXCL Agonists & Antagonists
• Dengue Virus Vaccines
• EGF-R Agonists and Antagonists
• Enzyme Replacement Therapies
• Erythropoiesis Stimulating Agents
• G-CSF and GM-CSF
• HDAC Inhibitors
• HDL Raising Therapies
• Heat shock protein 90 (Hsp90) Inhibitors
• HPV Vaccines
• Human Growth Hormone
• IGF-1R Antagonists
• Insulin
• Interferon
• Interleukin-17 and IL-17R Antagonists
• Janus Kinase (JAK) Inhibitors
• Malaria Vaccines
• NGF Agonists & Antagonists
• Novel Mitotic Kinase Inhibitors
• PDGF-R Agonists and Antagonists
• PI3K-AKT-mTOR Inhibitors
• Ras-Raf-MEK-ERK Inhibitors
• Targeted Therapy of Hepatitis C
• TGF-R Agonists and Antagonists
• TNF Agonists & Antagonists
• Toll-Like Receptor (TLR) Agonists and Antagonists
• VEGF and VEGF-R Agonists and Antagonists

Know more about this report at – http://mrr.cm/ZvY

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Pharmaceutical Business Confidence Report Q4 2014, New Report Launched

Pharmaceutical Business Confidence Report Q4 2014 that globally analyzes industry opinions on the latest economic and customer issues, and their impact on investment decisions and growth prospects within the pharmaceutical industry over October-December 2014. This report also examines executive opinions with regards to the current and future state of the economy and its effect on the industry. It analyzes the likely effect of supplier price changes, sales performance, and staff headcount within the industry. Furthermore, this report provides an overview of the key priorities, threats, and opportunities for the global pharmaceutical industry. In addition, the report includes the forecasts of the projected investments on pharmaceutical equipment, procurement budget allocations and the leading suppliers of pharmaceutical equipment in the pharmaceutical industry.

Key Findings

• Overall, 46% of pharmaceutical industry respondents state that they are operating in a stable economic environment, while 42% state that their current economic conditions are favorable
• The majority of global pharmaceutical industry respondents anticipate positive growth for both their companies and the industry over October-December 2014
• Industry respondents from Asia-Pacific expect the highest growth in staff headcount and sales volume in October-December 2014
• Improving operational efficiency and protecting and growing market share are the most popular priorities by pharmaceutical industry executives operating across all regions
• Highest percentage, 79%, of the survey respondents operating in Europe gives high preference for outright purchase in Q4 2014, while 21% of the respondents show less preference
• Respondents intend to allocate the biggest part of their procurement budget towards meeting operating expenses in 2015
• Survey results indicated that 35% of the survey respondents invest on the laboratory instrument every year.

Synopsis

This report is the result of an extensive survey drawn from Publisher's exclusive panel of leading global pharmaceutical industry executives. The report analyzes current global economic conditions and their impact on the pharmaceutical industry, and forecasts the company and industry growth prospects over October-December 2014. It provides information about the impact of customer confidence, supplier prices, and staff headcount likely to affect investment decisions October-December 2014. Additionally, the report includes the trends in the pharmaceutical equipment market, analysis of the procurement budget allocations and leading suppliers of pharmaceutical equipment.

In particular, it provides an in-depth analysis of the following:

• Industry executives' opinions about the current state of the global economy, examining the prevailing economic conditions and executives' opinions with regards to the global economy and the state of economic conditions in various regions
• The growth prospects of companies and the industry as a whole, providing industry executives' expectations on the growth prospects of their company and the Industry over October-December 2014
• Change in customer confidence, analyzing pharmaceutical industry executives' opinions on changes in customer confidence globally, over October-December 2014
• Impact of supplier prices, determining the expected change in supplier prices across various categories and their impact on business confidence, and examines the key factors influencing the change
• Change in staff headcount and sales performance, tracking the expected changes in staff headcount and sales among industry executives operating in various regions, over October-December 2014
• Investment activities, ascertaining the various investment activities on which industry executives intend to focus on over October-December 2014
• Business concerns, examining industry executives' attitudes towards various business concerns and provides regional analysis
• Key priorities, identifying the immediate business priorities of pharmaceutical industry executives over October-December 2014
• Purchase preferences: analyzing the purchasing behavior towards pharmaceutical equipment and investment allocations in the pharmaceutical equipment categories
• Budget allocation: examining total procurement budget split between capital expenditure and operating expenditure, and tracking the changes in the budget for 2014 and expectations for 2015.

Reasons to Buy

• The report projects the current and future operating conditions of the pharmaceutical industry, and allows readers to make effective business decisions
• The report helps readers make strategic decisions by understanding the present and future economic and customer issues, including key growth regions
• Pharmaceutical industry suppliers will be provided with a clear uncovering of the key challenges and opportunities, and identify the key priorities likely to affect the industry's growth prospects
• The report forecasts the change in supplier prices of various products, which are likely to influence the industry's growth prospects over October-December 2014
• The report helps executives to recognize the change in customer confidence levels in the global pharmaceutical industry over October-December 2014
• The report enables the executives to take key decisions on purchase preferences and investments in pharmaceutical equipment.

Spanning over 73 pages, “Pharmaceutical Business Confidence Report Q4 2014” report covering the Methodology and sample size, Confidence indexes, State of the economy, Growth prospects and customer confidence, Supplier prices and levels of expenditure, Organizational outlook and strategy, Procurement budget and expenditure outlook, Appendix. The report covered companies are - AstraZeneca , Pharmacyclics , Janssen Research and Development , Johnson and Johnson , Alios BioPharma , Galecto Biotech, GlaxoSmithKline, Bristol-Myers Squibb

For more information see – http://mrr.cm/ZtC

Related Report:

1st- Mining Business Confidence Report Q4 2014 - visit at: http://mrr.cm/Zty